A multi-center open-label pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec?c (imatinib)- resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL
Clinical Trial for Investigational Treatment
Not Recruiting
18 years or below
All
Phase
N/A
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Leukemia
Age:
18 years or below
Gender: All
Who can participate: Adults aged 18-65 with a diagnosis of the relevant condition are eligible. Participants should not have any severe uncontrolled medical conditions or be pregnant.
Study details: Participants will receive either the investigational treatment or a placebo, which is an inactive substance used for comparison. The trial involves regular monitoring and assessments to track the treatment's effects.
Updated on
19 Feb 2024.
Study ID: 1011004134
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
